To the full analysis
Innovent Biologics stock: growth
1801.HKInnovent Biologics reported $1.96B in revenue for fiscal 2025, up 38.4% on the prior year, up 27.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
94.9%
per year from 2016 to 2025, per share 85.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 27.7% | 94.9% |
| Revenue per share | 21.5% | 85.7% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $4.82M | −$75.61M | −$63.2M |
| 2017 | $2.78M | −$84.33M | −$87.47M |
| 2018 | $1.42M | −$865.52M | −$199.27M |
| 2019 | $157.09M | −$257.93M | −$304.48M |
| 2020 | $576.43M | −$149.73M | −$161.88M |
| 2021 | $640.31M | −$409.22M | −$580.71M |
| 2022 | $683.29M | −$326.81M | −$494.96M |
| 2023 | $930.69M | −$154.15M | −$185.3M |
| 2024 | $1.41B | −$14.19M | −$62.74M |
| 2025 | $1.96B | $122.01M | $1.4B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 19 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.